Seto D, Chodosh J, Brister JR, Jones MS, Members of the Adenovirus Research Community. 2011. Using the whole-genome sequence to characterize and name human adenoviruses. J Virol 85:5701-5702. https://doi .org/10.1128/JVI.00354-11.
Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG. 1953. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 84:570-573. https:// doi.org/10.3181/00379727-84-20714.
Huebner RJ, Rowe WP, Ward TG, Parrott RH, Bell JA. 1954. Adenoidal-pharyngeal- conjunctival agents. N Engl J Med 251:1077-1086. https://doi .org/10.1056/NEJM195412302512701.
Enders JF, Bell JA, Dingle JH, Francis T, Hilleman MR, Huebner RJ, Payne AM-M. 1956. Adenoviruses: group name proposed for new respiratorytract viruses. Science 124:119-120. https://doi.org/10.1126/science.124 .3212.119.
Radke JR, Cook JL. 2018. Human adenovirus infections: update and consideration of mechanisms of viral persistence. Curr Opin Infect Dis 31:251-256. https://doi.org/10.1097/QCO.0000000000000451.
Crenshaw BJ, Jones LB, Bell CR, Kumar S, Matthews QL. 2019. Perspective on adenoviruses: epidemiology, pathogenicity, and gene therapy. Biomedicines 7:61. https://doi.org/10.3390/biomedicines7030061.
Binder AM. 2017. Human adenovirus surveillance - United States, 2003- 2016. MMWR Morb Mortal Wkly Rep 66. https://doi.org/10.15585/mmwr .mm6639a2.
Lion T. 2014. Adenovirus infections in immunocompetent and immunocompromised patients. Clin Microbiol Rev 27:441-462. https://doi.org/10 .1128/CMR.00116-13.
Florescu DF, Hoffman JA, The AST Infectious Diseases Community of Practice. 2013. Adenovirus in Solid Organ Transplantation. Am J Transplant 13:206-211. https://doi.org/10.1111/ajt.12112.
Van Der Veen J, Lambriex M. 1973. Relationship of adenovirus to lymphocytes in naturally infected human tonsils and adenoids. Infect Immun 7:604-609. https://doi.org/10.1128/IAI.7.4.604-609.1973.
Garnett CT, Erdman D, Xu W, Gooding LR. 2002. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol 76:10608-10616. https://doi.org/10.1128/jvi.76.21.10608-10616.2002.
Garnett CT, Talekar G, Mahr JA, Huang W, Zhang Y, Ornelles DA, Gooding LR. 2009. Latent species C adenoviruses in human tonsil tissues. J Virol 83:2417-2428. https://doi.org/10.1128/JVI.02392-08.
Roy S, Calcedo R, Medina-Jaszek A, Keough M, Peng H, Wilson JM. 2011. Adenoviruses in lymphocytes of the human gastro-intestinal tract. PLoS One 6:e24859. https://doi.org/10.1371/journal.pone.0024859.
Kosulin K, Geiger E, Vécsei A, Huber W-D, Rauch M, Brenner E, Wrba F, Hammer K, Innerhofer A, Pötschger U, Lawitschka A, Matthes-Leodolter S, Fritsch G, Lion T. 2016. Persistence and reactivation of human adenoviruses in the gastrointestinal tract. Clin Microbiol Infect 22:381.e1-381.e8. https://doi.org/10.1016/j.cmi.2015.12.013.
Zhang Y, Huang W, Ornelles DA, Gooding LR. 2010. Modeling adenovirus latency in human lymphocyte cell lines. J Virol 84:8799-8810. https://doi .org/10.1128/JVI.00562-10.
Wold WSM, Toth K. 2014. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 13:421-433. https://doi .org/10.2174/1566523213666131125095046.
Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ. 1993. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75:207-216. https://doi.org/10.1016/0092-8674(93)80063-k.
Krammer F. 2020. SARS-CoV-2 vaccines in development. Nature 586:516-527. https://doi.org/10.1038/s41586-020-2798-3.
Hendrickx R, Stichling N, Koelen J, Kuryk L, Lipiec A, Greber UF. 2014. Innate immunity to adenovirus. Hum Gene Ther 25:265-284. https://doi .org/10.1089/hum.2014.001.
Greber UF, Flatt JW. 2019. Adenovirus entry: from infection to immunity. Annu Rev Virol 6:177-197. https://doi.org/10.1146/annurev-virology -092818-015550.
Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N. 2002. An anthropoid-specific locus of orphan C to U RNAediting enzymes on chromosome
Willems L, Gillet NA. 2015. APOBEC3 interference during replication of viral genomes. Viruses 7:2999-3018. https://doi.org/10.3390/v7062757.
Münk C, Willemsen A, Bravo IG. 2012. An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol Biol 12:71. https://doi.org/10.1186/1471-2148-12-71.
Nakano Y, Aso H, Soper A, Yamada E, Moriwaki M, Juarez-Fernandez G, Koyanagi Y, Sato K. 2017. A conflict of interest: the evolutionary arms race between mammalian APOBEC3 and lentiviral Vif. Retrovirology 14:31. https://doi.org/10.1186/s12977-017-0355-4.
Lackey L, Law EK, Brown WL, Harris RS. 2013. Subcellular localization of the APOBEC3 proteins during mitosis and implications for genomic DNA deamination. Cell Cycle 12:762-772. https://doi.org/10.4161/cc.23713.
Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650. https://doi.org/10.1038/nature00939.
Turelli P, Mangeat B, Jost S, Vianin S, Trono D. 2004. Inhibition of Hepatitis B virus replication by APOBEC3G. Science 303:1829-1829. https://doi.org/ 10.1126/science.1092066.
Sasada A, Takaori-Kondo A, Shirakawa K, Kobayashi M, Abudu A, Hishizawa M, Imada K, Tanaka Y, Uchiyama T. 2005. APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology 2:32. https://doi.org/10 .1186/1742-4690-2-32.
Chen H, Lilley CE, Yu Q, Lee DV, Chou J, Narvaiza I, Landau NR, Weitzman MD. 2006. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr Biol 16:480-485. https://doi.org/10.1016/j.cub .2006.01.031.
Vartanian J-P, Guétard D, Henry M, Wain-Hobson S. 2008. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 320:230-233. https://doi.org/10.1126/science .1153201.
Narvaiza I, Linfesty DC, Greener BN, Hakata Y, Pintel DJ, Logue E, Landau NR, Weitzman MD. 2009. Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog 5:e1000439. https://doi.org/10.1371/journal.ppat.1000439.
Tsuge M, Noguchi C, Akiyama R, Matsushita M, Kunihiro K, Tanaka S, Abe H, Mitsui F, Kitamura S, Hatakeyama T, Kimura T, Miki D, Hiraga N, Imamura M, Takahashi S, Hayses CN, Chayama K. 2010. G to A hypermutation of TT virus. Virus Res 149:211-216. https://doi.org/10.1016/j.virusres .2010.01.019.
Suspène R, Aynaud M-M, Koch S, Pasdeloup D, Labetoulle M, Gaertner B, Vartanian J-P, Meyerhans A, Wain-Hobson S. 2011. Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo. J Virol 85:7594-7602. https://doi .org/10.1128/JVI.00290-11.
Fehrholz M, Kendl S, Prifert C, Weissbrich B, Lemon K, Rennick L, Duprex PW, Rima BK, Koning FA, Holmes RK, Malim MH, Schneider-Schaulies J. 2012. The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses. J Gen Virol 93:565-576. https:// doi.org/10.1099/vir.0.038919-0.
Zhu Y-P, Peng Z-G, Wu Z-Y, Li J-R, Huang M-H, Si S-Y, Jiang J-D. 2015. Host APOBEC3G protein inhibits HCV replication through direct binding at NS3. PLoS One 10:e0121608. https://doi.org/10.1371/journal.pone.0121608.
Verhalen B, Starrett GJ, Harris RS, Jiang M. 2016. Functional upregulation of the DNA cytosine deaminase APOBEC3B by polyomaviruses. J Virol 90:6379-6386. https://doi.org/10.1128/JVI.00771-16.
Peretti A, Geoghegan EM, Pastrana DV, Smola S, Feld P, Sauter M, Lohse S, Ramesh M, Lim ES, Wang D, Borgogna C, FitzGerald PC, Bliskovsky V, Starrett GJ, Law EK, Harris RS, Killian JK, Zhu J, Pineda M, Meltzer PS, Boldorini R, Gariglio M, Buck CB. 2018. Characterization of BK polyomaviruses from kidney transplant recipients suggests a role for APOBEC3 in driving in-host virus evolution. Cell Host Microbe 23:628-635.e7. https:// doi.org/10.1016/j.chom.2018.04.005.
Milewska A, Kindler E, Vkovski P, Zeglen S, Ochman M, Thiel V, Rajfur Z, Pyrc K. 2018. APOBEC3-mediated restriction of RNA virus replication. Sci Rep 8:5960. https://doi.org/10.1038/s41598-018-24448-2.
Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ, Rada C, Stratton MR, Neuberger MS. 2013. DNA deaminases induce breakassociated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife 2:e00534. https://doi.org/10.7554/eLife .00534.
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale A-L, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Imielinsk M, Jäger N, Jones DTW, Jones D, Knappskog S, KoolM, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer Consortium, ICGC MMMLSeq Consortium, ICGC PedBrain, et al. 2013. Signatures of mutational processes in human cancer. Nature 500:415-421. https://doi.org/10 .1038/nature12477.
Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, Refsland EW, Kotandeniya D, Tretyakova N, Nikas JB, Yee D, Temiz NA, Donohue DE, McDougle RM, Brown WL, Law EK, Harris RS. 2013. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494:366-370. https://doi.org/10.1038/nature11881.
Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. 2014. APOBECmediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 7:1833-1841. https://doi.org/10.1016/j.celrep.2014.05.012.
Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, Boot A, Covington KR, Gordenin DA, Bergstrom EN, Islam SMA, Lopez-Bigas N, Klimczak LJ, McPherson JR, Morganella S, Sabarinathan R, Wheeler DA, Mustonen V, Getz G, Rozen SG, Stratton MR, PCAWG Consortium. 2020. The repertoire of mutational signatures in human cancer. Nature 578:94-101. https://doi.org/10.1038/s41586-020-1943-3.
Chan K, Roberts SA, Klimczak LJ, Sterling JF, Saini N, Malc EP, Kim J, Kwiatkowski DJ, Fargo DC, Mieczkowski PA, Getz G, Gordenin DA. 2015. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. Nat Genet 47:1067-1072. https://doi.org/10.1038/ng.3378.
Law EK, Levin-Klein R, Jarvis MC, KimH, Argyris PP, CarpenterMA, Starrett GJ, Temiz NA, Larson LK, Durfee C, Burns MB, Vogel RI, Stavrou S, Aguilera AN, Wagner S, Largaespada DA, Starr TK, Ross SR, Harris RS. 2020. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo. J Exp Med 217:e20200261. https://doi.org/10.1084/jem.20200261.
McDaniel YZ, Wang D, Love RP, Adolph MB, Mohammadzadeh N, Chelico L, Mansky LM. 2020. Deamination hotspots among APOBEC3 family members are defined by both target site sequence context and ssDNA secondary structure. Nucleic Acids Res https://doi.org/10.1093/ nar/gkz1164.
Anwar F, Davenport MP, Ebrahimi D. 2013. Footprint of APOBEC3 on the genome of human retroelements. J Virol 87:8195-8204. https://doi.org/ 10.1128/JVI.00298-13.
Warren CJ, Van Doorslaer K, Pandey A, Espinosa JM, Pyeon D. 2015. Role of the host restriction factor APOBEC3 on papillomavirus evolution. Virus Evol 1:vev015. https://doi.org/10.1093/ve/vev015.
Chen J, MacCarthy T. 2017. The preferred nucleotide contexts of the AID/APOBEC cytidine deaminases have differential effects when mutating retrotransposon and virus sequences compared to host genes. PLoS Comput Biol 13:e1005471. https://doi.org/10.1371/journal .pcbi.1005471.
Poulain F, Lejeune N, Willemart K, Gillet NA. 2020. Footprint of the host restriction factors APOBEC3 on the genome of human viruses. PLoS Pathog 16:e1008718. https://doi.org/10.1371/journal.ppat.1008718.
Ibelgaufts H, Doerfler W, Scheidtmann KH, Wechsler W. 1980. Adenovirus type 12-induced rat tumor cells of neuroepithelial origin: persistence and expression of the viral genome. J Virol 33:423-437. https://doi.org/10 .1128/JVI.33.1.423-437.1980.
Kuhlmann I, Achten S, Rudolph R, Doerfler W. 1982. Tumor induction by human adenovirus type 12 in hamsters: loss of the viral genome from adenovirus type 12-induced tumor cells is compatible with tumor formation. EMBO J 1:79-86. https://doi.org/10.1002/j.1460-2075.1982.tb01128.x.
Hohlweg U, Dorn A, Hösel M, Webb D, Buettner R, Doerfler W. 2004. Tumorigenesis by adenovirus type 12 in newborn Syrian hamsters, p 215-244. In Doerfler, W, Böhm, P ( ed), Adenoviruses: model and vectors in virus-host interactions. Springer, Berlin, Heidelberg.
Caval V, Suspène R, Shapira M, Vartanian J-P, Wain-Hobson S. 2014. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage. Nat Commun 5:5129. https://doi.org/10.1038/ncomms6129.
Xiao X, Yang H, Arutiunian V, Fang Y, Besse G, Morimoto C, Zirkle B, Chen XS. 2017. Structural determinants of APOBEC3B non-catalytic domain for molecular assembly and catalytic regulation. Nucleic Acids Res 45:7494-7506. https://doi.org/10.1093/nar/gkx362.
Vieira VC, Leonard B, White EA, Starrett GJ, Temiz NA, Lorenz LD, Lee D, Soares MA, Lambert PF, Howley PM, Harris RS. 2014. Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. mBio 5:e02234-14. https://doi.org/10.1128/mBio .02234-14.
Pebernard S, Iggo RD. 2004. Determinants of interferon-stimulated gene induction by RNAi vectors. Differentiation 72:103-111. https://doi.org/10 .1111/j.1432-0436.2004.07202001.x.
Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou W-M, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. 2014. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343:1221-1228. https://doi.org/10.1126/science.1243462.
Kanu N, Cerone MA, Goh G, Zalmas L-P, Bartkova J, Dietzen M, McGranahan N, Rogers R, Law EK, Gromova I, Kschischo M, Walton MI, Rossanese OW, Bartek J, Harris RS, Venkatesan S, Swanton C. 2016. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biol 17:185. https://doi.org/10.1186/s13059-016-1042-9.
Siriwardena SU, Perera MLW, Senevirathne V, Stewart J, Bhagwat AS. 2018. A tumor-promoting phorbol ester causes a large increase in APOBEC3A expression and a moderate increase in APOBEC3B expression in a normal human keratinocyte cell line without increasing genomic uracils. Mol Cell Biol 39. https://doi.org/10.1128/MCB.00238-18.
Yamazaki H, Shirakawa K, Matsumoto T, Kazuma Y, Matsui H, Horisawa Y, Stanford E, Sarca AD, Shirakawa R, Shindo K, Takaori-Kondo A. 2020. APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression. PLoS One 15:e0223463. https://doi .org/10.1371/journal.pone.0223463.
Leonard B, McCann JL, Starrett GJ, Kosyakovsky L, Luengas EM, Molan AM, Burns MB, McDougle RM, Parker PJ, Brown WL, Harris RS. 2015. The PKC/NF-κB signaling pathway induces APOBEC3B expression in multiple human cancers. Cancer Res 75:4538-4547. https://doi.org/10.1158/0008-5472.CAN-15-2171-T.
Maruyama W, Shirakawa K, Matsui H, Matsumoto T, Yamazaki H, Sarca AD, Kazuma Y, Kobayashi M, Shindo K, Takaori-Kondo A. 2016. Classical NF-κB pathway is responsible for APOBEC3B expression in cancer cells. Biochem Biophys Res Commun 478:1466-1471. https://doi.org/10.1016/j .bbrc.2016.08.148.
Periyasamy M, Singh AK, Gemma C, Kranjec C, Farzan R, Leach DA, Navaratnam N, Pálinkás HL, Vértessy BG, Fenton TR, Doorbar J, Fuller- Pace F, Meek DW, Coombes RC, Buluwela L, Ali S. 2017. p53 controls expression of the DNA deaminase APOBEC3B to limit its potential mutagenic activity in cancer cells. Nucleic Acids Res 45:11056-11069. https:// doi.org/10.1093/nar/gkx721.
Roelofs PA, Goh CY, Chua BH, Jarvis MC, Stewart TA, McCann JL, McDougle RM, Carpenter MA, Martens JW, Span PN, Kappei D, Harris RS. 2020. Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B. Elife 9. https://doi.org/10 .7554/eLife.61287.
Warren CJ, Xu T, Guo K, Griffin LM, Westrich JA, Lee D, Lambert PF, Santiago ML, Pyeon D. 2015. APOBEC3A functions as a restriction factor of human papillomavirus. J Virol 89:688-702. https://doi.org/10.1128/JVI .02383-14.
Mori S, Takeuchi T, Ishii Y, Yugawa T, Kiyono T, Nishina H, Kukimoto I. 2017. Human papillomavirus 16 E6 upregulates APOBEC3B via the TEAD transcription factor. J Virol 91. https://doi.org/10.1128/JVI.02413-16.
Westrich JA, Warren CJ, Klausner MJ, Guo K, Liu C-W, Santiago ML, Pyeon D. 2018. Human papillomavirus 16 E7 stabilizes APOBEC3A protein by inhibiting cullin 2-dependent protein degradation. J Virol 92:e01318-17. https://doi.org/10.1128/JVI.01318-17.
Sullivan CS, Baker AE, Pipas JM. 2004. Simian virus 40 infection disrupts p130-E2F and p107-E2F complexes but does not perturb pRb-E2F complexes. Virology 320:218-228. https://doi.org/10.1016/j.virol.2003 .10.035.
DeCaprio JA. 2014. Human papillomavirus type 16 E7 perturbs DREAM to promote cellular proliferation and mitotic gene expression. Oncogene 33:4036-4038. https://doi.org/10.1038/onc.2013.449.
Rashid NN, Rothan HA, Yusoff MSM. 2015. The association of mammalian DREAM complex and HPV16 E7 proteins. Am J Cancer Res 5:3525-3533.
Fischer M, Uxa S, Stanko C, Magin TM, Engeland K. 2017. Human papilloma virus E7 oncoprotein abrogates the p53-p21-DREAM pathway. Sci Rep 7:2603. https://doi.org/10.1038/s41598-017-02831-9.
Starrett GJ, Serebrenik AA, Roelofs PA, McCann JL, Verhalen B, Jarvis MC, Stewart TA, Law EK, Krupp A, Jiang M, Martens JWM, Cahir-McFarland E, Span PN, Harris RS. 2019. Polyomavirus T antigen induces APOBEC3B expression using an LXCXE-dependent and TP53-independent mechanism. mBio 10. https://doi.org/10.1128/ mBio.02690-18.
Pelka P, Miller MS, Cecchini M, Yousef AF, Bowdish DM, Dick F, Whyte P, Mymryk JS. 2011. Adenovirus E1A directly targets the E2F/DP-1 complex. J Virol 85:8841-8851. https://doi.org/10.1128/JVI.00539-11.
Ghosh MK, Harter ML. 2003. A viral mechanism for remodeling chromatin structure in G0 cells. Mol Cell 12:255-260. https://doi.org/10.1016/s1097-2765(03)00225-9.
Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D, Kaelin WG, Conaway RC, Conaway JW, Branton PE. 2001. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev 15:3104-3117. https:// doi.org/10.1101/gad.926401.
Harada JN, Shevchenko A, Shevchenko A, Pallas DC, Berk AJ. 2002. Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery. J Virol 76:9194-9206. https://doi.org/10.1128/jvi.76 .18.9194-9206.2002.
Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu X-F. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060. https://doi.org/10.1126/science.1089591.
Gilson T, Blanchette P, Ballmann MZ, Papp T, Pénzes JJ, Benko M, Harrach B, Branton PE. 2016. Using the E4orf6-based E3 ubiquitin ligase as a tool to analyze the evolution of adenoviruses. J Virol 90:7350-7367. https:// doi.org/10.1128/JVI.00420-16.
Hirose Y, Onuki M, Tenjimbayashi Y, Mori S, Ishii Y, Takeuchi T, Tasaka N, Satoh T, Morisada T, Iwata T, Miyamoto S, Matsumoto K, Sekizawa A, Kukimoto I. 2018. Within-host variations of human papillomavirus reveal APOBEC-signature mutagenesis in the viral genome. J Virol 92:e00017-18. https://doi.org/10.1128/JVI.00017-18.
Vartanian J-P, Henry M, Marchio A, Suspène R, Aynaud M-M, Guétard D, Cervantes-Gonzalez M, Battiston C, Mazzaferro V, Pineau P, Dejean A, Wain-Hobson S. 2010. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog 6:e1000928. https://doi.org/10.1371/journal .ppat.1000928.
Robinson CM, Seto D, Jones MS, Dyer DW, Chodosh J. 2011. Molecular evolution of human species D adenoviruses. Infect Genet Evol 11:1208-1217. https://doi.org/10.1016/j.meegid.2011.04.031.
Robinson CM, Singh G, Lee JY, Dehghan S, Rajaiya J, Liu EB, Yousuf MA, Betensky RA, Jones MS, Dyer DW, Seto D, Chodosh J. 2013. Molecular evolution of human adenoviruses. Sci Rep 3:1812. https://doi.org/10.1038/ srep01812.
Dicks MDJ, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, Hill AVS, Cottingham MG. 2012. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One 7:e40385. https://doi.org/10 .1371/journal.pone.0040385.
Riu E, Chen Z-Y, Xu H, He C-Y, Kay MA. 2007. Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo. Mol Ther 15:1348-1355. https://doi.org/10.1038/ sj.mt.6300177.
Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, Dimaio JM, Milchgrub S, Smith AL, Souza RF, Gilbey L, Zhang X, Gandia K, Vaughan MB, Wright WE, Gazdar AF, Shay JW, Minna JD. 2004. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64:9027-9034. https://doi.org/10.1158/ 0008-5472.CAN-04-3703.
Wissing S, Montano M, Garcia-Perez JL, Moran JV, Greene WC. 2011. Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells. J Biol Chem 286:36427-36437. https://doi.org/10.1074/jbc.M111.251058.
Law EK, Sieuwerts AM, LaPara K, Leonard B, Starrett GJ, Molan AM, Temiz NA, Vogel RI, Meijer-van Gelder ME, Sweep FCGJ, Span PN, Foekens JA, Martens JWM, Yee D, Harris RS. 2016. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci Adv 2:e1601737. https://doi.org/10.1126/sciadv .1601737.
Huang C, Kolokoltsova OA, Mateer EJ, Koma T, Paessler S. 2017. Highly pathogenic new world arenavirus infection activates the pattern recognition receptor protein kinase R without attenuating virus replication in human cells. J Virol 91:e01090-17. https://doi.org/10.1128/JVI .01090-17.
Wang S-L, Chi C-Y, Kuo P-H, Tsai H-P, Wang S-M, Liu C-C, Su I-J, Wang J-R. 2013. High-incidence of human adenoviral co-infections in Taiwan. PLoS One 8:e75208. https://doi.org/10.1371/journal.pone.0075208.
Refsland EW, Stenglein MD, Shindo K, Albin JS, Brown WL, Harris RS. 2010. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 38:4274-4284. https://doi.org/10.1093/nar/gkq174.
